All News

In light of new evidence supporting the efficacy of hepatitis C virus (HCV) treatments in individuals who use or inject drugs, researchers are urging the removal of restrictions that prevent recent drug users from accessing lifesaving HCV therapies.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Brain inflammation caused by critical illness and infection may lead to the observed reduction in brain volume.

The Drug Enforcement Administration is placing Epidiolex in Schedule V, the least restrictive of the Controlled Substances Act

Two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack are being voluntarily recalled by Endo Pharmaceuticals Inc., due to incorrent dosing information on the label.

Latest approval for carfilzomib offers a more convenient dosing option for patients with multiple myeloma.

A high-touch patient care model with enhanced data collection may help stop the ongoing opioid problem.

Metabolic syndrome involves multiple disease states including hypertension, hyperlipidemia, and possibly diabetes.

The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

According to FDA Commissioner Scott Gottlieb, MD, the agency’s approval of amikacin liposome inhalation suspension marks an important policy milestone.

Lymphatic vessels surrounding the brain may play a key role in the development and progression of multiple sclerosis.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Officials with the FDA have approved Admais’ 0.15mg Symjepi for the emergency treatment of allergic reactions, including anaphylaxis, in children.

A global survey found that 2 of 3 individuals with type 2 diabetes had experienced a cardiovascular disease (CVD) event or had CVD risk factors.

The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria in a limited population of patients with the disease who do not respond to conventional treatment.

Officials with the FDA have approved cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation.

Cemiplimab-rwlc (Libtayo) is the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma in the United States.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA®, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

Get involved this October and show your appreciation for the work pharmacists do.

Dacomitinib tablets (Vizimpro, Pfizer) received FDA approval for the first-line treatment of patients with metastatic non-small cell lung cancer.

The FDA has approved Eli Lilly’s preventive migraine treatment galcanezumab-gnlm (Emgality).

Pregnant women take herbal and natural products (HNPs) as alternatives to prescription medications, but, HNPs have active ingredients and drug interactions that can potentially cause harm to both the mother and her baby.

Dacomitinib (Vizimpro, Pfizer) is indicated for patients with non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Galcanezumab-gnlm (Emgality), a once monthly, self-administered 120-mg subcutaneous injection, is indicated for the preventive treatment of migraine in adults.

Top news of the week from Specialty Pharmacy Times.